CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit

BOSTON, Sept. 8, 2018 /PRNewswire/ — CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class CAR-Claudin18.2 T cell trial for treatment of pancreatic and…

Source: https://www.prnewswire.com:443/news-releases/carsgen-presents-car-claudin18-2-t-data-at-2018-car-tcr-summit-300709170.html